Randomised controlled trial of scalp cooling for the prevention of chemotherapy induced alopecia

Randomized controlled trials (RCT) of scalp cooling (SC) to prevent chemotherapy induced alopecia (CIA) did not evaluate its effect on hair regrowth (HR) and was conducted in a predominantly taxane (T) treated population. We conducted an RCT of SC in a setting of anthracycline (A) and taxane chemoth...

Full description

Saved in:
Bibliographic Details
Published in:Breast (Edinburgh) 2020-02, Vol.49, p.187-193
Main Authors: Bajpai, J., Kagwade, S., Chandrasekharan, A., Dandekar, S., Kanan, S., Kembhavi, Y., Ghosh, J., Banavali, S.D., Gupta, S.
Format: Article
Language:English
Subjects:
Alopecia
Breast cancer
Chemotherapy
Original
Quality of life
Scalp cooling
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Randomized controlled trials (RCT) of scalp cooling (SC) to prevent chemotherapy induced alopecia (CIA) did not evaluate its effect on hair regrowth (HR) and was conducted in a predominantly taxane (T) treated population. We conducted an RCT of SC in a setting of anthracycline (A) and taxane chemotherapy (CT) and assessed its effect on CIA and HR. Non-metastatic breast cancer women undergoing (neo) adjuvant CT were randomized to receive SC using the Paxman scalp cooling system during every cycle of CT, or no SC. The primary end point (PEP) was successful hair preservation (HP) assessed clinically and by review of photographs after CT. HR was assessed at 6 and 12 weeks. 51 patients were randomized to SC (34) or control arm (17) in a 2:1 ratio. Twenty-five (49%) patients received A followed by T and the two arms were balanced with respect to this factor. HP rate was significantly higher in SC arm compared to control arm (56.3% vs 0%, P = 0.000004). HR was higher in SC arm compared to control at 6 weeks (89% vs 12%; P 
ISSN:0960-9776
1532-3080
DOI:10.1016/j.breast.2019.12.004